ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2323

Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity

Yoshiya Tanaka1, Kazuhiko Yamamoto2, Tsutomu Takeuchi3, Hisashi Yamanaka4, Naoki Ishiguro5, Katsumi Eguchi6, Akira Watanabe7, Hideki Origasa8, Tadao Okamoto9, Yumiko Wada9, Toshiharu Shoji9, Nobuyuki Miyasaka10 and Takao Koike11, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, 3Keio University, Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5Department of Orthopedic Surgery, Nagoya University, Nagoya, Japan, 6Sasebo City General Hospital, Sasebo, Japan, 7Tohoku University, Sendai, Japan, 8Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, 9UCB Pharma, Tokyo, Japan, 10Department of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Tokyo, Japan, 11NTT Sapporo Medical Center, Sapporo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACR, anti-TNF therapy, certolizumab pegol and rheumatoid arthritis (RA), Japanese

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The therapeutic goals of treating rheumatoid arthritis (RA) are clinical, structural and functional remissions.1,2 Simultaneously achieving all three has been referred to as comprehensive disease remission (CDR). Certolizumab pegol (CZP) has demonstrated rapid and sustained improvement in disease activity and inhibition of structural damage in 2 double-blind (DB) trials, J-RAPID3 (with MTX; NCT00791999) and HIKARI4 (without MTX; NCT00791921), and in subsequent open-label extensions (OLE; NCT00851318 and NCT00850343, respectively) in Japanese patients (pts). This post-hoc analysis evaluated CDR achievement in RA pts with high baseline disease activity treated with CZP. Factors associated with CZP CDR at OLE Wk52 were also investigated.

 

Methods:

CDR was defined as simultaneous achievement of DAS28(ESR) ≤2.6 (DAS remission), HAQ-DI ≤0.5 (HAQ remission) and yearly change in (Δ) mTSS ≤0.5 (radiographic non-progression), while comprehensive disease control (CDC) was defined by substituting DAS28(ESR) <3.2 in CDR. CDC/CDR of CZP vs placebo (PBO), with and without MTX, were evaluated at Wk24 of DB trials on the full analysis set (FAS) population of CZP (200mg every 2 weeks [Q2W]; approved dose) and PBO groups in J-RAPID (CZP n=82, PBO n=77) and HIKARI (CZP n=116, PBO n=114). Additionally, CZP CDC/CDR were evaluated at OLE entry and Wk52 for DB CZP 200mg Q2W pts who entered OLE studies (J-RAPID n=74, HIKARI n=105; FAS). Factors associated with CZP CDC/CDR at OLE Wk52 were analyzed for all DB CZP pts, regardless of dose, who entered OLE (J-RAPID n=215, HIKARI n=105; FAS), using several Wk12 clinical response measures eg. DAS28(ESR) disease activity and HAQ.

Results :

CDC and CDR at Wk24 of J-RAPID were 28.0% and 13.4% for CZP, and 5.2% and 0% fo PBO, respectively (Table). In HIKARI, 25.0% and 15.5% CZP pts achieved CDC and CDR at Wk24 vs 0% and 0% PBO pts, respectively. In HIKARI, CZP was shown to be similarly effective in attaining CDR as monotherapy (9/54, 16.7%) or with concomitant non-MTX DMARDs (9/62, 14.5%). CDC and CDR at OLE Wk52 were 37.8% and 24.3% in J-RAPID, and 28.6% and 21.9% in HIKARI, respectively (Table). Of pts with DAS remission at Wk12, 50% (14/28) and 50% (8/16) achieved CDR at OLE Wk52 in J-RAPID and HIKARI, respectively. Similarly, 35% (J-RAPID 43/124) and 31% (HIKARI 19/62) of pts with Wk12 HAQ remission  achieved CDR at OLE Wk52.

Conclusion :

CZP treatment demonstrated high rates of CDC/CDR at Wk24 and OLE Wk52 in RA pts with high baseline disease activity. CZP treatment, regardless of concomitant MTX or as monotherapy, was effective in achieving CDC/CDR. Wk12 DAS or HAQ remission with CZP was associated with high achievement of CDR at OLE Wk52.

References:

1. Smolen J.S. Ann Rheum Dis 2010;69(6):964-975; 2. Singh J. Arthritis Care Res 2012;64(5):625-639; 3. Yamamoto K. Arthritis Rheum 2011;63(Supp10):S474; 4. Yamamoto K. Arthritis Rheum 2011;63(Supp10):S476


Disclosure:

Y. Tanaka,

BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbvie, Daiichi-Sankyo,

2,

UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

8,

UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

5;

K. Yamamoto,

UCB Pharma, Pfizer, Abbott, BMS, Roche, Chugai, Mitsubishi-Tanabe and Eisai,

5,

UCB Pharma, Pfizer, Abbott, Santen, Mitsubishi-Tanabe and Eisai,

2;

T. Takeuchi,

AstraZeneca, Eli Lilly, Novartis, Mitsubishi-Tanabe and Asahi Kasei,

5,

Abott, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Janssen, Mitsubishi-Tanabe, Nippon Shinyaku, Otsuka, Pfizer, Sanofi-Aventis, Santen, Takeda and Teijin,

2,

UCB Pharma, Abbott, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,

8;

H. Yamanaka,

UCB Pharma, Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,

2,

UCB Pharma, Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,

5;

N. Ishiguro,

Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken and Pfizer,

2,

Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken, Pfizer, Taisho-Toyama and Otsuka,

8;

K. Eguchi,

UCB Pharma.,

5;

A. Watanabe,

Daiichi-Sankyo, Kyorin, Shionogi, Taisho, Dainippon-Sumitomo, Taiho, Toyama Chemical and Meiji Seika,

2,

MSD, GSK, Shionogi, Daiichi-Sankyo, Taisho-Toyama, Dainippon-Sumitomo, Mitsubishi-Tanabe, Pfizer,

8;

H. Origasa,

UCB Pharma and Astellas,

5;

T. Okamoto,

UCB Pharma,

3;

Y. Wada,

UCB Pharma,

3;

T. Shoji,

UCB Pharma,

3;

N. Miyasaka,

Pfizer, Takeda, Mitsubishi-Tanabe, Chugai, Abbott, Eisai and Astellas,

2;

T. Koike,

UCB Pharma, Pfizer, Chugai, Abbott, Mitsubishi-Tanabe, Takeda, Eisai, Santen, Astellas, Taisho-Toyama, BMS, Teijin and Daiichi-Sankyo,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comprehensive-disease-remission-achieved-by-certolizumab-pegol-treatment-and-factors-associated-with-certolizumab-pegol-comprehensive-disease-remission-in-rheumatoid-arthritis-patients-with-predomin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology